+

WO1992015327A1 - Immunotoxines bicatenaires de recombinaison - Google Patents

Immunotoxines bicatenaires de recombinaison Download PDF

Info

Publication number
WO1992015327A1
WO1992015327A1 PCT/US1992/001784 US9201784W WO9215327A1 WO 1992015327 A1 WO1992015327 A1 WO 1992015327A1 US 9201784 W US9201784 W US 9201784W WO 9215327 A1 WO9215327 A1 WO 9215327A1
Authority
WO
WIPO (PCT)
Prior art keywords
immunotoxin
toxin
tac
composition
antigen binding
Prior art date
Application number
PCT/US1992/001784
Other languages
English (en)
Inventor
Chung Nan Chang
Cary L. Queen
Original Assignee
Protein Design Labs, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs, Inc. filed Critical Protein Design Labs, Inc.
Publication of WO1992015327A1 publication Critical patent/WO1992015327A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Definitions

  • the present invention relates generally to recombinant double chain immunotoxins and methods for their production and use.
  • An immunotoxin is a chimeric compound consisting of a toxin linked to an antibody having a single desired specificity, notably characteristic antigenic determinants expressed on the surface of certain cells, including microorganisms, neoplastic cells, virally infected cells, and subsets of normal cells.
  • Such antibodies thus act as targeting agents for the toxin, allowing it to act cell-specifically (for reviews, see I. Pastan et al.. Cell 12:641-648 (1986); and E. Vitetta et al.. Science 238:1098-1104 (1987), both incorporated herein by reference) .
  • Toxins are products of nature usually produced by bacteria and plants (S. Olsnes and A. Pihl, in Molecular Action of Toxins and Viruses. P. Cohen and S. van Heyningen, eds. (Elsevier, New York, 1982), p. 503, incorporated herein by reference) . .Among the best studied and roost widely employed toxins are the plant-derived toxic lectins, notably ricin, but also including abrin and modeccin. Toxic lectins consist of two polypeptide chains, A and B, linked by disulfide bridge(s), of which the A chain is cytotoxic via its ability to block ribosomal protein synthesis in eukaryotic cells.
  • the B chain recognizes polysaccharide units at the cell surface and creates a high affinity binding to such units.
  • the complex of toxin and cell surface glycoprotein to which it is bound is endocytosed, the disulfide bond between the A and B chains is reduced, and the A chain translocates across an endocytic membrane to gain access to the cytosol.
  • Other toxins including bacterial toxins (e.g., diphtheria toxin), have also been studied. Some of these, such as Pseudomonas Exotoxin A, consist of a single polypeptide chain having both binding and cytotoxic activities.
  • immunotoxins have been made with one of a limited class of toxins that act to directly inhibit protein synthesis by inactivating ribosomes (e.g., ricin) or elongation-factor-2 (e.g., diphtheria toxin, Pseudomonas exotoxin A) .
  • ribosomes e.g., ricin
  • elongation-factor-2 e.g., diphtheria toxin, Pseudomonas exotoxin A
  • Immunotoxins prepared with ricin or its A chain have been most widely used to date, and the ricin A chain is usually coupled to a cell-reactive antibody by chemically cross-linking ricin or its A chain to the antibody, e.g., through thioether linkages.
  • immunotoxins made with intact ricin appear to be prohibitively toxic for systemic administration (E. Vitetta et al. (1987)).
  • immunotoxins containing only the ricin A chain have extraordinarily, but show unpredictable cytotoxicity because of the absence of B chain-mediated potentiation of A chain translocation (Reviewed in Immunol. Rev. 62. (1982) . See also. R. Youle and D. Neville, Jr., J. Biol. Chem. 257:1598 (1982); and D. Mclntosh et al., Fed. Eur. Biochem. Soc. 164:17 (1983); all incorporated herein by reference) .
  • Immunotoxins made with antibodies directed toward tumor-associated antigens or lymphoid markers can selectively eliminate cancer cells or subsets of lymphoid cells in vitro and in vivo. Such immunotoxins hold considerable promise for the treatment of cancer and autoimmune conditions in human patients. However, in actual clinical trials with cancer patients, the benefits have so far been very modest (E. Vitetta et al. (1987)). This lack of dramatic clinical success has been attributed to the inaccessibility of the tumor tissue to the large immunotoxin molecules, and to insufficient toxicity of the immunotoxin toward cancer cells relative to normal cells.
  • immunotoxins have commonly been made by chemically attaching a toxin to an intact antibody containing the constant region of the antibody, which is not necessary for immunotoxin action, but which reduces its access to target cells outside the circulation, and increases its immunogenicity.
  • the product is heterogenous and unstable, and the yields are often poor.
  • a single chain immunotoxin was prepared by recombinant means, namely a single chain anti-Tac(Fv)-PE40 having the two variable regions joined by a linker and the toxin polypeptide in peptide linkage with one of the two variable segments (V. Chaudhary et al., Nature 339:394 (1989), incorporated herein by reference) .
  • Immunotoxins exhibiting improved characteristics are still actively sought for a number of reasons. Immunotoxins coupled by chemical conjugation are heterogenous and unstable, and thus may be dangerous to the patient. They are also relatively expensive to produce. Small, single-chain immunotoxins have a relatively short half-life, which typically impairs efficiency. Moreover, the unnatural links between variable domains in the single chain recombinant immunotoxin often leads to a reduced affinity for the antigenic determinant recognized by the antigen binding site. There exists a need, therefore, for improved immunotoxin compositions that avoid the problems associated with chemically coupling toxin moieties to immunoglobulins, while also providing the advantages of higher affinities for the target cell and a longer half-life. One would thus be able to maintain efficacy at lower doses, reducing side effects of treatment.
  • the present invention fulfills these and other needs.
  • FIG. 1 Schematic diagram of anti-Tac(Fab)-PLC genetic construct (SEQ. ID NOS:l and 2). Not drawn to scale. The mature protein coding sequences are shaded. The DNA linker between PLC and the anti-Tac heavy chain is shown with Apal and BstEII sites underlined. Relevant restriction sites are indicated.
  • STII E. coli heat-stable enterotoxin II; S.D., Shine and Dalgarno sequence; E, EcoRI; A, Apal; B, BstEII; X, Xbal; M, Mlul.
  • Fig. 2 Purification of anti-Tac(Fab)-PLC. Samples were analyzed on a 10% SDS polyacrylamide gel and stained with Coomassie blue. Lane 1, osmotic shock fluid, non-reduced; lane 2, purified anti-Tac(Fab)-PLC, non-reduced; lane 3, protein markers with molecular weights 94, 67, 43, 30, 20, 14 kD, reduced; lane 4, purified anti-Tac(Fab)-PLC, reduced. The arrow indicates the light chain band of 25 kD. Fig. 3. Competitive binding of anti-Tac and anti-
  • Tac(Fab)-PLC to HuT-102 cells.
  • ⁇ anti-Tac competitor; •, anti- Tac(Fab)-PLC competitor.
  • FIG. 5 Schematic diagram of the anti-Tac(Fab)-PE40 immunotoxin.
  • V variable domain of anti-Tac heavy chain
  • V variable domain of anti-Tac light chain
  • Cl first constant domain of anti-Tac heavy chain
  • C L constant domain of anti-Tac light chain
  • S-S disulfide bond
  • PE40 Pseudomonas exotoxin- 40.
  • Fig. 6 Schematic diagram of DNA construct for anti- Tac (Fab)-PE40 (SEQ. ID NOS:3 and 4). Protein designations as in Fig. 5.
  • the linker sequence inserted between V C and PE40 is shown, with the Ncol site underlined.
  • STII E. coli heat stable enterotoxin II; S.D., Shine and Dalgarno sequence; E, EcoRI; B, BstEII; X, Xbal; M, Mlul; N, Ncol.
  • Fig. 7 Cytotoxicity of anti-Tac(Fab)-PE40 'alone (•) and with 10 ⁇ g/ml anti-Tac antibody (O) on HuT-102 cells.
  • the present invention provides recombinant double chain immunotoxins comprising two components, an antigen binding component and a bacterial toxin polypeptide component.
  • the antigen binding component is formed from two polypeptide chains (preferably immunoglobulin heavy and light chains) , each chain comprising complementarity determining regions (CDRs) in an immunoglobulin framework region.
  • CDRs complementarity determining regions
  • Preferred examples of such two chain antigen binding components are Fv and Fab with one chain being in peptide linkage to a bacterial toxin polypeptide component, which may be an enzyme, such as phospholipase C, or PE40.
  • the antigen binding component may also be chimeric or humanized.
  • a humanized antigen binding component will have a human immunoglobulin framework region, and the CDRs may be from a different immunoglobulin than the framework region.
  • the antigen binding site preferably binds specifically to an antigen on a cell surface, such as those on the surface of neoplastic cells or T cells, for example the Tac antigen.
  • nucleic acids encoding such immunotoxins preferably comprising expression vectors in which a promoter is operably linked to a sequence encoding the immunotoxin; cells transformed with such expression vectors; compositions comprising such immunotoxins in a pharmaceutically acceptable carrier; and methods of treating a mammal comprising administering a therapeutically effective dose of such compositions.
  • the immunotoxin compositions of the present invention comprise recombinant double chain antigen binding components, preferably immunoglobulins and their fragments, and bacterial toxin components in peptide linkage to one or both chains.
  • double chain it is understood that the immunotoxin comprises two polypeptide chains, i.e., not connected by a peptide bond, which may, however, be linked by disulfide bridges.
  • recombinant it is understood that the entire immunotoxin may be synthesized in a cell from DNA segments produced by genetic engineering.
  • recombinant immunotoxins would not comprise chemical cross-linkers such as N-succinimidyl-3-(2- pyridydithio)propionate (SPDP) , thioether bonds, and the like.
  • SPDP N-succinimidyl-3-(2- pyridydithio)propionate
  • Complete antibodies are included as antigen binding components of such immunotoxin compositions.
  • the basic antibody structural unit is known to comprise a tetramer.
  • Each tetramer is composed of two iden ⁇ tical pairs of polypeptide chains, each pair having one "light” (about 25kD) and one "heavy" chain (about 50-70kD) .
  • the amino- terminus of each chain begins a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
  • the carboxy-terminus of each chain defines a constant region primarily responsible for effector function. (See, generally, Fundamental Immunology. Paul, W. , Ed. , Chapter 7, pgs. 131-166, Raven Press, N.Y. (1984), which is incorporated herein by reference.)
  • an “antigen binding component”, as the term is used in the present invention, comprises that part of an immunoglobulin capable of specifically binding an antigen, and is formed by two immunoglobulin chains. It is preferably formed from the variable regions of each light/heavy chain pair, although antigen binding by heavy chain dimers, as well as single chains has been observed.
  • the chains all exhibit the same general structure of relatively conserved framework regions joined by three hypervariable regions, also called CDR's (see. "Sequences of Proteins of Immunological Interest,” Kabat, E. et al., U.S. Department of Health and Human Services, (1983); and Chothia and Lesk, J. Mol. Biol., 196:901-917 (1987), which are incorporated herein by reference).
  • the CDR's from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope.
  • immunoglobulin refers to a protein consisting of one or more polypeptide ⁇ substantially encoded by immunoglobulin genes.
  • the recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes.
  • Immunoglobulins may exist in a variety of two-chain forms besides complete antibodies; including various forms of modified or altered antibodies, for example: an Fv fragment, containing only the light and heavy chain variable regions; an Fab or (Fab 1 ) fragment, containing the variable regions and parts of the constant regions (See, generally. Hood et al.. Immunology.
  • the antigen binding components of the present invention may be of animal (especially mouse or rat) , but preferably of human origin, or combinations of these as in chimeric or humanized immunoglobulins.
  • animal especially mouse or rat
  • human origin or combinations of these as in chimeric or humanized immunoglobulins.
  • the extensive investigation of immunoglobulin genes and their products has provided a diverse set of polypeptides exhibiting various antibody activities. For a review, see. G. Winter and C.
  • “Chimeric” antibodies are antibodies whose light and heavy chain genes have been constructed, typically by genetic engineering, from immunoglobulin gene segments belonging to different species (S. Morrison et al., Proc. Natl. Acad. Sci. USA 181:6851-6855 (1984); incorporated herein by reference).
  • V variable
  • C constant
  • a typical chimeric antibody is thus a hybrid protein consisting of the V or antigen-binding domain from a mouse antibody and the C or effector domain from a human antibody (e.g.. A.T.C.C. Accession No. CRL 9688 secretes an anti-Tac chimeric antibody) , although other mammalian species may be used.
  • framework region refers to those portions of immunoglobulin light and heavy chain variable regions that are relatively conserved fi.e.. other than the CDR's) among different immunoglobulins in a single species, as defined by Kabat et al. (1983).
  • a "human framework region” is a framework region that in each existing chain comprises at least about 70 or more amino acid residues, typically 75 to 85 or more residues, identical to those in a human immunoglobulin.
  • humanized or “human-like” immunoglobulin refers to an immunoglobalin comprising a human framework region and in which any constant region present is substantially identical to a human immunoglobulin constant region (Jones et al.. Nature 3_21:522-526, (1986), incorporated herein by reference), i.e.. at least about 85-90%, preferably about 95% identical.
  • all parts of a human-like immunoglobulin, except possibly the CDR's are substantially identical to corresponding parts of one or more native human immunoglobulin sequences.
  • An antigen specifically recognized or bound by an antigen binding component may have a wide variety of chemical structures, including peptides, nucleic acids, carbohydrates, lipids, and combinations of these (e.g., glycoproteins) .
  • the antigens are membrane constituents on selected cell populations, such as neoplastic cells or T cells. More specifically, proteins on the membranes of some or all T cells that can serve as targets for the immunotoxins described here include CD2 (Til), CD3, CD4 (on helper T cells) and the IL-2 receptor (see. Leukocyte Typing III. A. J. McMichael, ed. , Oxford University Press, 1987, incorporated herein by reference) , and the alpha and beta chains of the T cell receptor. Proteins found predominantly on B cells that might serve as targets include CD10 (CALLA antigen), CD19 and CD20. CD45 is a possible target that occurs broadly on lymphoid cells.
  • Antigens found on cancer cells that might serve as targets include carcinoembryonic antigen (CEA) , the erbB-2 (also called HER-2) receptor, the transferrin receptor, and the antigens recognized by 17-1A antibody (Herlyn et al., Proc. Natl. Acad. Sci. USA, 76.:1438, 1979, incorporated herein by reference), L6 antibody (Hellstrom et al. , Cancer Res. 46:3917- 3923, (1986), incorporated herein by reference) and B6.2 antibody (Colcher et al., Proc. Natl. Acad. Sci. USA, 78:3199, (1981) , incorporated herein by reference) .
  • CCA carcinoembryonic antigen
  • erbB-2 also called HER-2
  • transferrin receptor the antigens recognized by 17-1A antibody
  • L6 antibody Hellstrom et al. , Cancer Res. 46:3917- 3923, (1986), incorporated herein
  • the preferred toxin components of the immunotoxin polypeptides of the present invention are bacterial polypeptide toxins (see. The Specificity and Action of Animal. Bacterial and Plant Toxins. P. Cuatrecasas (ed.), London, Chapman and Hall (1976) , incorporated herein by reference) .
  • Many useful toxins act to directly inhibit protein synthesis, e.g., by inactivating elongation factor-2 (diptheria toxin, Pseudomonas exotoxin A) .
  • These toxins must be internalized into the cytoplasm, and may have cell binding domains which may be removed to prevent unacceptable toxicity toward normal cells.
  • Pseudomonas exotoxin (PE) may be modified to remove its binding domain (thus forming PE40) .
  • PLC phospholipase C
  • PLC phospholipase C
  • a detailed description of immunotoxins capable of damaging cell membranes can be found in the commonly assigned pending patent application U.S. serial number 07/380,172 filed July 14, 1989, which is incorporated herein by reference.
  • Additional suitable bacterial toxins include those listed in Table 1 (all citations incorporated herein by reference) , and Shigella toxin, botulinum toxin, tetanus toxin, cholera toxin, and E.coli heat-stable and heat-labile toxins.
  • Toxin components of the immunotoxin polypeptides are in peptide linkage, i.e., connected by a peptide bond, with the 5* or 3' end of either or both of the two chains forming the antigen binding site of these polypeptides, for example, with the heavy chain or light chain.
  • nucleic acids encoding and expressing the immunotoxins of the present invention the sequences encoding the toxin component and a chain of the antigen binding component are in the same reading frame and operably linked to the same promoter; when expressed, both components form part of the same polypeptide chain.
  • a nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence.
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence.
  • operably linked means that the DNA sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame.
  • Dimers (or higher multimers) of double chain recombinant immunotoxins may be formed, e.g., by disulfide bonds in the hinge region of the heavy chain constant domain. Such dimers can have the same relation to double chain recombinant immunotoxin monomers as (Fab') fragments have to Fab fragments of antibodies. Although containing more than two chains, such dimers and multimers are comprised by the term "double chain recombinant immunotoxin," because their minimal active constituent units are such. Double chain recombinant immunotoxins can also be linked, genetically or chemically, to other protein domains to provide additional functions.
  • the nucleic acids of the present invention include those encoding or expressing recombinant double chain immunotoxin polypeptides. These may be used to transform or transfect appropriate host cells for various purposes (e.g., production of the claimed immunotoxin polypeptides) .
  • the recombinant immunotoxin polypeptides of the present invention may be made by synthetic polypeptide methods or more preferably by recombinant nucleic acid methods.
  • Suitable synthetic DNA fragments may be prepared by the phosphoramidite method described by Beaucage and Carruthers, Tetra. Letts. .22.:1859-1862 (1981), incorporated herein by reference.
  • a double stranded fragment may then be obtained by annealing the strands together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.
  • nucleic acid manipulation such as subcloning nucleic acid sequences encoding polypeptides into vectors and the isolation of substantially pure nucleic acids, are described generally in Sambrook et al. , Molecular Cloning: A Laboratory Manual (2nd ed.), Vols. 1-3, Cold Spring Harbor Laboratory, (1989) or Current Protocols in Molecular Biology. F. Ausubel et al., ed. Greene Publishing and Wiley-
  • nucleic acid sequences used to produce fusion proteins of the present invention may be derived from natural or synthetic sequences.
  • a nucleic acid is termed "isolated" or rendered
  • substantially pure when purified away from other cellular components or other contaminants, e.g., other cellular nucleic acids or proteins, by standard techniques, including alkaline/SDS treatment, CsCl banding, column chromatography, and others well known in the art. See. Current Protocols in Molecular Biology (1987) .
  • PCR polymerase chain reaction
  • Useful probes and primers may be selected from published sequences in accordance with published procedures.
  • Synthetic oligonucleotides can be formulated by the triester method according to Matteucci et al., J. Am. Chem. Soc,
  • Nucleic acid probes used for constructing nucleic acids encoding the polypeptide components of the immunotoxins of the present invention, for obtaining sequences encoding naturally occurring components from cDNA or genomic libraries, or other purposes will include an isolated nucleic acid attached to a label or reporter molecule. Probes may be prepared by nick translation, Klenow fill-in reaction, random hexamer priming, or other methods known in the art. For making probes, see, e.g.. Current Protocols in Molecular Biology (1987) .
  • Human constant region DNA sequences can be isolated in accordance with well known procedures from a variety of human cells, but preferably immortalized B-cells (see. Kabat (1983) and WP87/02671) .
  • immortalized B-cells see. Kabat (1983) and WP87/02671 .
  • the human kappa immunoglobulin constant and J region genes and sequences are described in Heiter et al.. Cell 22.:197-207 (1980) and the nucleotide sequence of a human immunoglobulin C gene is described in Ellison et al., Nucl. Acid. Res. .10:4071 (1982), both of which are incorporated herein by reference.
  • variable regions or CDR's for producing the antigen binding components of the present invention will be similarly derived from hybridomas producing monoclonal antibodies capable of binding to the desired antigen (e.g., the human IL-2 receptor) and produced by well-known methods in any convenient mammalian source, including, mice, rats, rabbits, or other vertebrate capable of producing antibodies.
  • Suitable source cells for the DNA sequences and host cells for immunoglobulin expression and secretion can be obtained from a number of sources, such as the .American Type Culture Collection ("Catalogue of Cell Lines and Hybridomas," Fifth edition (1985) Rockville, Maryland; U.S.A., which is incorporated herein by reference) .
  • substantially homologous modified immunotoxins can be readily designed and manufactured utilizing various recombinant DNA techniques well known to those skilled in the art.
  • modifications of the genes may be readily accomplished by a variety of well-known techniques, such as site-directed mutagenesis (see. Gillman and Smith, Gene 1:81-97 (1979) and S. Roberts et al, Nature 328:731-734 (1987), both of which are incorporated herein by reference) .
  • site-directed mutagenesis see. Gillman and Smith, Gene 1:81-97 (1979) and S. Roberts et al, Nature 328:731-734 (1987), both of which are incorporated herein by reference.
  • Such additional modifications, deletions, insertions and the like may be made to the sequences encoding the antigen binding and toxin components of the immunotoxins of the present invention, as will be readily appreciated by those skilled in the art.
  • deletions or changes may be made in toxin-encoding sequences or in the linker connecting a chain of the antigen-binding component to the toxin, in order to increase the cytotoxicity of the fusion protein toward target cells or to decrease nonspecific cytotoxicity toward cells without antigen for the antibody.
  • All such constructions may be made by methods of genetic engineering well known to those skilled in the art and may produce proteins that have differing properties of affinity, specificity, stability and toxicity that make them particularly suitable for various clinical or biological applications.
  • sequences encoding the two chains of the double chain recombinant immunotoxin may be contained on a single vector or on separate vectors. Moreover the recombinant immunotoxin after synthesis may remain internal to the E. coli host cell until purified. In another embodiment of the invention, the sequences encoding these polypeptides may be preceded by a signal sequence that directs their secretion from the cell (Better et al., Science 240:1041-1043 (1988); Skerra & Pluckthun, Science 240:1038-1041 (1988), both incorporated herein by reference) .
  • the immunoglobulin- related genes contain separate functional regions, each having one or more distinct biological activities
  • the sequence encoding an immunoglobulin chain forming the antigen binding component of the present invention may be fused to functional regions from other genes (e.g., different toxin components, marker genes, etc.) to produce fusion proteins having novel properties.
  • Recombinant methods for polypeptide synthesis commence with the construction of a replicable vector containing nucleic acid that encodes the polypeptide.
  • Vectors typically facilitate the cloning of the nucleic acid encoding the immunotoxin, i.e., to produce usable quantities of the nucleic acid. If a vector is an expression vector, it also directs the expression of the immunotoxin. One or both of these functions are performed by the vector-host system. The vectors will contain different components depending upon the function they are to perform as well as the host cell that is selected.
  • DNA expression vectors incorporating coding regions for a polypeptide will most preferably be suitable for replication in a unicellular host, such as bacteria or possibly a yeast, but may also be intended for introduction to, and possibly introduction into the genome of, a cultured mammalian or plant or other eukaryotic cell lines.
  • Such vectors will typically include a replication system recognized by the host, including an origin of replication or autonomously replicating sequence (ARS) , the intended DNA fragment encoding the desired polypeptide, and transcription and translational initiation regulatory sequences operably linked to the polypeptide encoding segment.
  • ARS autonomously replicating sequence
  • the transcriptional regulatory sequences may include a promoter, heterologous enhancer and necessary processing information sites, RNA splice sites, polyadenylation sites, transcriptional terminator sequences and mRNA stabilizing sequences, all of which are recognized by the host.
  • the polypeptide encoding segment may be preceded by such translational initiation sequences such as ribosome-binding sites.
  • Such expression vectors may also include secretion signals from secreted polypeptides of the same or related species, which allow the protein to cross cell membranes, and thus attain its functional topology.
  • bacterial promoters such as the phoA, trp, lac and phage promoters, tRNA promoters and glycolytic enzyme promoters are known and commonly used
  • yeast promoters include the promoter regions for metallothionein; 3-phosphoglycerate kinase or other glycolytic enzymes such as enolase, glyceraldehyde-3-phosphate dehydrogenase; enzymes responsible for maltose and galactose utilization; and other:-. Suitable vectors and promoters for use in yeast expression are further described in R. Hitzeman et al., EP 73,657A, incorporated herein by reference.
  • non-native mammalian promoters might include the early and late promoters of SV40 or promoters derived from mouse mammary tumor virus, avian sarcoma viruses, adenovirus II, bovine papilloma virus or polyoma virus, among others. Examples of workable combinations of cell lines and expression vectors are described in Molecular Cloning: A Laboratory Manual (2nd ed.) (1989); see also. Metzger et al., Nature 334:31 (1989), incorporated herein by reference.
  • the DNA sequences will be expressed in hosts after the sequences have been operably linked to (i.e.. positioned to ensure the functioning of) an expression control sequence.
  • These expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA.
  • expression vectors will contain selectable markers, genes encoding a protein necessary for the survival or growth of a host cell transformed with the vector. The presence of this gene ensures the growth of only those host cells which express the marker activity.
  • Typical selectable marker genes encode proteins that (a) confer resistance to antibiotics or other toxic substances, e.g., ampicillin, neomycin, methotrexate, etc.; (b) complement auxotrophic deficiencies; or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.
  • antibiotics or other toxic substances e.g., ampicillin, neomycin, methotrexate, etc.
  • auxotrophic deficiencies e.g., auxotrophic deficiencies
  • c supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.
  • the choice of the proper selectable marker will depend on the host cell, and appropriate markers for different hosts are well known in the art (see, e.g.. U.S. Patent 4,704,362, which is incorporated herein by reference) .
  • E. coli is one prokaryotic host useful particularly for cloning the DNA sequences of the present invention.
  • Other microbial hosts suitable for use include bacilli, such as Bacillus subtilus. and other enterobacteriaceae, such as
  • Salmonella. Serratia. and various Pseudomonas species may also be used for expression.
  • yeast e.g., Saccharomyces
  • mammalian tissue cell culture may also be used to express and produce the polypeptides of the present invention (see. Winnacker, From Genes to Clones. VCH Publishers, N.Y., N.Y. (1987), which is incorporated herein by reference) .
  • suitable host cell lines capable of secreting intact immunoglobulins have been developed in the art, and include the CHO cell lines, various COS cell lines, HeLa cells, myeloma cell lines, etc, but preferably transformed B-cells or hybridomas.
  • transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; infection (where the vector is an infectious agent or capable of being mobilized to another cell by functions supplied in trans) ; microinjection; and other methods are commonly utilized (See, generally. Molecular Cloning: A Laboratory Manual (2nd ed.) (1989), or Current Protocols in Molecular Biology (1987)).
  • the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and, as desired, the collection and purification of the double chain recombinant immunotoxin may follow.
  • polypeptides may then be used therapeutically (including extracorporeally) or other purposes (See, generally. Immunological Methods. Vols. I and II, Lefkovits and Pernis, eds., Academic Press, New York, N.Y. (1979 and 1981)) .
  • immunotoxin compositions of the present invention may also be used in combination with other antibodies, or immunotoxins, particularly human monoclonal antibodies reactive with other markers on cells responsible for the disease.
  • suitable T-cell markers can include those grouped into the so-called "Clusters of Differentiation,” as named by the First International Leukocyte Differentiation Workshop,
  • the immunotoxin compositions can also be used as separately administered compositions given in conjunction with chemotherapeutic or immunosuppressive agents.
  • the agents will include cyclosporin A or a purine analog (e.g.. methotrexate, 6-mercaptopurine, or the like) , but numerous additional agents (e.g.. cyclophosphamide, prednisone, etc.) well-known to those skilled in the art may also be utilized.
  • cyclophosphamide, prednisone, etc. well-known to those skilled in the art may also be utilized.
  • intact immunoglobulins or their binding fragments, such as Fv or Fab are preferably used. When entire antibodies are employed, they will typically be of the human IgM or IgG isotype, but other mammalian constant regions may be utilized as desired.
  • compositions of this invention are particularly useful for parenteral administration, i.e. , subcutaneously, intramuscularly or intravenously.
  • the compositions for parenteral administration will commonly comprise a solution of the immunotoxin or a cocktail thereof dissolved in an accept ⁇ able carrier, preferably an aqueous carrier.
  • an accept ⁇ able carrier preferably an aqueous carrier.
  • aqueous carriers can be used, e.g.. water, buffered water, 0.4% saline, 0.3% glycine and the like. These solutions are sterile and generally free of particulate matter.
  • These compositions may be sterilized by conventional, well known sterilization techniques.
  • compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as human albumin, pH adjusting and buffering agents, toxicity adjusting agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc.
  • concentration of immunotoxin in these formulations can vary widely, i.e.. from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
  • a typical pharmaceutical composition for intramuscular injection could be made up to contain 1 ml sterile buffered water, and 5 mg of immunotoxin.
  • a typical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 15 mg of immunotoxin.
  • Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in, for example, Remington's Pharmaceutical Science. 15th ed. , Mack Publishing Company, Easton, Pennsylvania (1980) , which is incorporated herein by reference.
  • the immunotoxin compositions of this invention can be lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional immune globulins and art-known lyophilization and reconstitution techniques can be employed.
  • lyophilization and reconstitution can lea to varying degrees loss of activity (e.g. , with conventional immune globulins, IgM antibodies tend to have greater activity loss than IgG antibodies) and that use levels may have to be adjusted to compensate.
  • compositions of the present invention or a cocktail thereof can be administered for prophylactic and/or therapeutic treatments.
  • compositions are administered to a patient already suffering from a disease, in an amount sufficient to cure or at least partially arrest the disease and its complications.
  • An amount adequate to accomplish this is defined as a "therapeutically effective dose.” Amounts effective for this use will depend upon the severity of the infection and the general state of the patient's own immune system, as well as on the particular immunotoxin employed in treatment and the therapeutic purpose, but typically range from about 0.1 to about 20 mg of immunotoxin per dose, with dosages of from 1 to 5 mg per patient being more commonly used. It must be kept in mind that the materials of this invention may generally be employed in serious disease states, that is life-threatening or potentially life-threatening situations. In such cases it is possible and may be felt desirable by the treating physician to administer substantial excesses of these immunotoxins.
  • compositions containing the present immunotoxins or a cocktail thereof are administered to a patient not already in a disease state to enhance the patient's resistance.
  • Such an amount is defined to be a "prophylactically effective dose.”
  • the precise amounts again depend upon the patient's state of health and general level of immunity, but generally range from 0.1 to 5 mg per dose, especially 0.5 to 2.5 mg per patient.
  • compositions can be carried out with dose levels and pattern being selected by the treating physician.
  • pharmaceutical formulations should provide a quantity of the immunotoxin(s) of this invention sufficient to effectively treat the patient.
  • An exemplary embodiment of the present invention is the use of immunotoxins directed against the IL-2 receptor.
  • the anti-Tac antibody recognizes the p55 chain of the human IL- 2 receptor (T. Uchiyama et al., J. Immunol. 126:1393-1397 (1981) , incorporated herein by reference) .
  • the IL-2 receptor specific immunotoxins exemplified in the present invention will typically find use individually in treating a T-cell mediated disease state. Generally, where the cell linked to a disease has been identified as IL-2 receptor bearing, such immunotoxins may be used.
  • typical disease states suitable for treatment include graft versus host disease and transplant rejection in patients undergoing an organ transplant, such as heart, lungs, kidneys, liver, etc.
  • other diseases include autoimmune diseases, such as Type I diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and myasthenia gravis; and malignancies such as adult T cell leukemia, Hodgkin's disease, and other lymphomas.
  • EXAMPLE 1 ANTI-TAC(Fab)-PLC
  • cytolytic toxins produced by many bacteria (J. Alouf, in: P. Cuatrecasas (ed.). The Specificity and Action of Animal. Bacterial and Plant Toxins, pp. 221-270. London. England: Chapman and Hall (1976)), which act by damaging the target cell membrane and thus do not have to be internalized.
  • PLC phospholipase C
  • PLC phospholipase C
  • PLC is a highly potent toxin that causes cell damage by hydrolyzing the phospholipid phospatidylcholine, a major membrane constituent (M. MacFarlane and B.
  • PLC has been linked to the Fab fragment of the anti- Tac antibody, which recognizes the p55 chain of the human IL-2 receptor (T. Uchiyama et al. (1981)), to produce an anti- Tac(Fab)-PLC immunotoxin.
  • Anti-Tac(Fab)-PLC specifically binds to and inhibits protein synthesis in human T cells expressing the IL-2 receptor.
  • Antibody Fab fragments can be expressed and secreted from E. coli (Better et al. (1988)). Hence, we attached the complete PLC gene with its own promoter and signal sequence (J. Tso and C. Siebel (1989)) to the V H-CH1 domains of the cloned anti-Tac heavy chain gene (C. Queen et al., Proc. Natl. Acad. Sci. USA ___6 :10029-10033 (1989), incorporated herein by reference) , followed by a termination codon (Fig. 1) . For ease of DNA manipulation and to provide a spacer between the PLC and antibody proteins, a 27 bp linker encoding 9 amino acids was inserted between PLC and Vn.
  • the CHl domain was followed on the same cistron by the mature anti-Tac light chain gene, attached to the Shine and Dalgarno (ribosome binding) sequence, initiation codon and signal coding sequence of E. coli heat- stable enterotoxin II (R. Picken et al., Infection and Immunity 42.:269-275 (1983), incorporated herein by reference).
  • PLC was fused to the amino rather than the carboxy end of the antibody because preliminary experiments had shown that the amino terminal end of PLC itself must be free if the enzyme is to retain activity. This transcriptional unit was inserted into the EcoRI site of pBR322, as described below.
  • the plasmid PLCTAC which encodes anti-Tac(Fab)-PLC, was constructed from five consecutive DNA fragments (Fig. 1) .
  • Fig. 1 First, in vitro mutagenesis in M13 (M. Zoller and M. Smith, Nucl. Acids Res. .10:6487-6500 (1982), incorporated herein by reference) was used to attach an Apal restriction site after the terminals Lys codon of the PLC gene (J. Tso and C. Siebel (1989)), and a fragment extending from an EcoRI site upstream of the PLC promoter down to the new Apal site was purified. In vitro mutagenesis in M13 was also used to modify the cDNA of the anti-Tac heavy chain (C. Queen et al.
  • the ST II Xbal - Mlul fragment was combined with the light chain Mlul - EcoRI fragment in the plasmid pUC19.
  • the combined EcoRI - Xbal fragment containing PLC and the heavy chain was then ligated with the combined Xbal - EcoRI fragment containing the ST II sequences and the light chain, and was inserted in the EcoRI site of pBR322 to produce PLCTAC.
  • Osmotic shock extract was prepared in HO as described (J. Tso and C. Siebel (1989)) from E. coli cells containing the plasmid PLCTAC, in order to isolate proteins located in the periplasmic space.
  • the extract was adjusted to 50 mM in Tris, pH 8.0 and applied to a column of Affi-Gel 10 coupled with rabbit anti-(mouse kappa -hain) antibody (Cappel) .
  • the column washed with 0.1 M glycine, pH 3.0.
  • Anti- Tac(Fab)-PLC was eluted with 3.5 M MgCl 2 and dialyzed against 20 mM Tris, pH 8.0.
  • Phospholipase C enzymatic activity was determined as described (J. Tso and C. Siebel (1989)), using an ethanoic dispersion of phosphatidylcholine substrate. One unit of activity equals one micromole of product formed per minute at 37 ⁇ C.
  • Hemolytic activity of PLC was determined using sheep erythrocytes as described (J. Tso and C. Siebel (1989)). One 50% hemolysis unit is the amount of enzyme that causes 50% hemolysis of the erythrocytes under the described conditions, measured spectrophotometrically at 550 nm.
  • the affinity of anti-Tac(Fab)-PLC for the IL-2 receptor was determined as described (C. Queen et al. (1989)). Briefly, increasing amounts of competitor (anti-Tac antibody or anti-Tac(Fab)-PLC) were added to 1.5 ng of radioiodinated tracer anti-Tac antibody (2 uCi/ug) and incubated with 4 x 10 5 Hut-102 cells in 0.2 ml binding buffer (RPMI 1040 medium with 10% fetal calf serum, murine Ig at 10 ug/ml, 0.1% sodium azide) for 2 hours at 0*C. Cells were washed and pelleted, their radioactivities measured, and the concentrations of bound and free tracer antibody calculated. The affinity constant of anti-Tac(Fab)-PLC was then calculated (C. Queen et al. (1989)).
  • the anti-Tac(Fab)-PLC protein was purified from the osmotic shock extract using a rabbit anti-(mouse kappa chain) affinity column, as described above. The resulting protein was about 90% pure as judged by a coomassie stained gel (Fig. 2) . The enzymatic and binding activities of the purified anti-Tac(Fab)- PLC protein were assessed.
  • the PLC in the anti-Tac(Fab)-PLC conjugate had about 4-fold less enzymatic activity on phosphatidylcholine and about 2-fold less hemolytic activity on sheep erythrocytes than free PLC (Table 2) .
  • Binding to IL-2 receptor was measured using Hut-102 cells, a human T-cell lymphoma line expressing the IL-2 receptor p55 chain at a high level (Uchiyama et al. (1981)). Increasing amounts of competitor (anti-Tac antibody or anti-tac(Fab)-PLC) were added to radio-labeled tracer anti-Tac and incubated with the Hut-102 cells (Fig. 3). The affinity constant of anti-Tac(Fab)-PLC was calculated as 8 x 10 7 M "1 versus 3 x 10 9 M "1 for anti-Tac itself, a 37-fold loss in affinity. TABLE 2 Specific activity of anti-Tac(Fab)-PLC a
  • the immunotoxin was tested for cytotoxicity on HuT- 102 cells (Fig. 4).
  • Anti-Tac(Fab)-PLC inhibited protein synthesis in a dose-dependent manner with 50% inhibitory concentration (IC ) of 0.02 nM (1.8 ng/ml) .
  • IC inhibitory concentration
  • the IC of PLC alone was 25 nM, so linking PLC to the anti-Tac targeting antibody increased its toxicity on HuT-102 cells by more than 1000-fold.
  • Competition with 10 ug/ml anti-Tac abolished the increased cytotoxicity of anti-Tac(Fab)-PLC, demonstrating specificity of targeting (Fig. 4) .
  • the human T-cell leukemia line CEM which does not express the Tac antigen p55, could not be inhibited by concentrations of anti- Tac(Fab)-PLC as high as 10 nM. It is important to note that the inhibition of protein synthesis measured by the cytotoxicity assay is an indirect result of cell membrane damage by PLC, rather than the direct enzymatic effect of toxins such as ricin. Hence, it is possible that this standard assay understates the effect of membrane-acting immunotoxins relative to conventional ones.
  • PLC a membrane-acting toxin
  • Anti-Tac(Fab)-PE40 is a recombinant, two-chain immunotoxin in which PE40 is genetically linked to the Fab fragment of anti-Tac (Fig. 5).
  • the plasmid pTACPE40 which encodes anti-Tac(Fab)-PE40, was constructed from five consecutive DNA fragments (Fig. 6) .
  • in vitro mutagenesis in M13 was used to create a BstEII site by mutating the third nucleotides encoding amino acids Pro (-5) and Thr (- 3) of the alkaline phosphatase (phoA) signal sequence, and a Hindlll site located 5' upstream of the phoA promoter was converted into an EcoRI site.
  • the resulting EcoRI-BstEII fragment contains the phoA promoter and signal codons.
  • In vitro mutagenesis in M13 was also used to modify the cDNA of the anti-Tac heavy chain: a BstEII site and codons for the amino acids Lys and Ala were inserted just 5' to the Gin codon that starts the mature coding sequence of the heavy chain, and a step codon and Xbal site were inserted immediately after the C 1 coding region.
  • the phoA EcoRI-BstEII fragment was combined with the anti-Tac heavy chain BstEII-Xbal fragment in the plasmid pUC19.
  • In vitro mutagenesis was also used to inser* a Ncol site just 5' to the Gly codon that starts domain II of the Pseudomonas exotoxin (PE40) gene.
  • the fragment extending from the Ncol site to an EcoRI site located at the 3' end of the PE gene was isolated.
  • the above- mentioned three fragments — the STII Xbal-Mlul fragment, the light chain Mlul-Ncol fragment, and the PE40 NcoI-EcoRI fragment — were combined in the plasmid pUC19.
  • the combined EcoRI-Xbal fragment containing the PhoA promoter and signal sequence and the heavy chain was then ligated with the combined Xbal-EcoRI fragment containing the STII sequence, the light chain and the PE40 sequence, and finally inserted in the EcoRI site of pBR322 to produce the plasmid pTACPE40.
  • Osmotic shock extract was prepared in HO as described previously (J. Tso & C. Siebel (1989)) from E. coli cells containing the plasmid pTACPE40, in order to isolate proteins located in the periplasmic space.
  • the extract was adjusted to 50 mM in Tris-HCl, pH 8.0 and applied to a column of Sepharose 4B coupled with rat anti-(mouse kappa light chain) antibody (Zymed) .
  • Anti-Tac(Fab)-PE40 was eluted with 3.5 M MgC12 and dialyzed against 20 mM Tris-HCl, pH 8.0.
  • the protein was estimated by SDS-polyacrylamide gel analysis to be 20% pure.
  • the anti-Tac(Fab)- PE40 is purified from the extract by chromatography on S- Sepharose in 25 mM MES, pH 6.5, eluting with 300 mM NaCl, and then by chromatography on Q-Sepharose in 20 mM bis-Tris, pH 6.5, eluting with a 0-400 mM NaCl gradient.
  • results are expressed as a percentage of the 3 H-leucine incorporation in control cultures, which have not been incubated with immunotoxin (Fig. 7) .
  • Competitor anti-Tac antibody prevents this inhibition, showing the specificity of anti-Tac(Fab)-PE40.
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Immunotoxines de recombinaison présentant un composant de liaison d'antigène bicaténaire, généralement une immunoglobuline ou une partie de cette substance, dont une chaîne présente une liaison peptidique avec une toxine bactérienne. On décrit également des compositions thérapeutiques et des procédés utilisant ces immunotoxines.
PCT/US1992/001784 1991-03-08 1992-03-06 Immunotoxines bicatenaires de recombinaison WO1992015327A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66628791A 1991-03-08 1991-03-08
US666,287 1991-03-08

Publications (1)

Publication Number Publication Date
WO1992015327A1 true WO1992015327A1 (fr) 1992-09-17

Family

ID=24673598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/001784 WO1992015327A1 (fr) 1991-03-08 1992-03-06 Immunotoxines bicatenaires de recombinaison

Country Status (2)

Country Link
AU (1) AU1582692A (fr)
WO (1) WO1992015327A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
EP0769957A1 (fr) * 1995-04-13 1997-05-02 Milkhaus Laboratory, Inc. Procedes de traitement des deficits moteurs
US5766886A (en) * 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US6632440B1 (en) 1998-08-25 2003-10-14 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
AU781677B2 (en) * 1999-11-12 2005-06-02 Syntaxin Limited Use of lytic toxins and toxin conjugates
US6962703B2 (en) 1995-04-21 2005-11-08 Ipsen Limited Clostridial toxin derivatives able to modify peripheral sensory afferent functions
US7052702B1 (en) 1997-10-08 2006-05-30 Health Protection Agency Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US7208466B1 (en) 1999-03-31 2007-04-24 The Health Protection Agency Use of a lectin or conjugates for modulation of c-fibre activity
US7674470B2 (en) 1996-08-23 2010-03-09 Health Protection Agency Recombinant toxin fragments
EP1969165A4 (fr) * 2005-12-23 2010-05-19 Viventia Biotech Inc Methodes pour generer et pour cribler des bibliotheques de proteines hybrides, et leurs utilisations
US7727538B2 (en) 1998-08-25 2010-06-01 Syntaxin Ltd. Methods and compounds for the treatment of mucus hypersecretion
US8012491B2 (en) 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
US8852603B2 (en) 1999-09-23 2014-10-07 Syntaxin Limited Inhibition of secretion from non-neuronal cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, Volume 51, issued 15 January 1991, CHOVNICK et al., "A recombinant, membrane-acting immunotoxin", pages 465-467. *
NATURE, Volume 339, issued 01 June 1989, CHAUDHARY et al., "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin", pages 394-397. *
PROC. NATL. ACAD. SCI. USA, issued 01 Feb 1990, CHAUDHARY et al., "A Rapid Method of Cloning Functional Variable-Region Antibody Genes in Escherichia Coli as Single-Chain Immunotoxins", pages 1066-1070. *
PROC. NATL. ACAD. SCI. USA, Volume 87, issued November 1990, KREITMAN et al., "The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia", pages 8291-8295. *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5744580A (en) * 1991-11-04 1998-04-28 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5756699A (en) * 1991-11-04 1998-05-26 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6376217B1 (en) 1991-11-04 2002-04-23 Xoma Technology Ltd. Fusion proteins and polynucleotides encoding gelonin sequences
US6146631A (en) * 1991-11-04 2000-11-14 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6649742B1 (en) 1991-11-04 2003-11-18 Xoma Technology Ltd. Immunotoxins comprising ribosome-inactivating proteins
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5821123A (en) * 1991-12-13 1998-10-13 Xoma Corporation Modified antibody variable domains
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5770196A (en) * 1991-12-13 1998-06-23 Xoma Corporation Modified antibody variable domains and therapeutic uses thereof
US5766886A (en) * 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
EP0769957A4 (fr) * 1995-04-13 1999-11-03 Milkhaus Lab Inc Procedes de traitement des deficits moteurs
EP0769957A1 (fr) * 1995-04-13 1997-05-02 Milkhaus Laboratory, Inc. Procedes de traitement des deficits moteurs
US7892560B2 (en) 1995-04-21 2011-02-22 Syntaxin, Ltd Clostridial toxin derivatives able to modify peripheral sensory afferent functions
US6962703B2 (en) 1995-04-21 2005-11-08 Ipsen Limited Clostridial toxin derivatives able to modify peripheral sensory afferent functions
US8158132B2 (en) 1995-04-21 2012-04-17 Syntaxin Limited Clostridial toxin derivatives able to modify peripheral sensory afferent functions
US7887810B2 (en) 1995-04-21 2011-02-15 Syntaxin, Ltd Clostridial toxin derivatives able to modify peripheral sensory afferent functions
US7897158B2 (en) 1996-08-23 2011-03-01 Syntaxin, Ltd Recombinant toxin fragments
US8454976B2 (en) 1996-08-23 2013-06-04 Syntaxin Limited Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US8017134B2 (en) 1996-08-23 2011-09-13 Syntaxin Limited Recombinant toxin fragments
US7674470B2 (en) 1996-08-23 2010-03-09 Health Protection Agency Recombinant toxin fragments
US8012479B2 (en) 1996-08-23 2011-09-06 Health Protection Agency Recombinant toxin fragments
US8012491B2 (en) 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
US7052702B1 (en) 1997-10-08 2006-05-30 Health Protection Agency Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
US7452543B2 (en) 1997-10-08 2008-11-18 Syntaxin Ltd. Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
US7727538B2 (en) 1998-08-25 2010-06-01 Syntaxin Ltd. Methods and compounds for the treatment of mucus hypersecretion
US6632440B1 (en) 1998-08-25 2003-10-14 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US7208466B1 (en) 1999-03-31 2007-04-24 The Health Protection Agency Use of a lectin or conjugates for modulation of c-fibre activity
US8852603B2 (en) 1999-09-23 2014-10-07 Syntaxin Limited Inhibition of secretion from non-neuronal cells
AU781677B2 (en) * 1999-11-12 2005-06-02 Syntaxin Limited Use of lytic toxins and toxin conjugates
US7422740B1 (en) 1999-11-12 2008-09-09 Health Protection Agency Use of lytic toxins and toxin conjugates
AU781677C (en) * 1999-11-12 2006-09-07 Syntaxin Limited Use of lytic toxins and toxin conjugates
US9006395B2 (en) 2002-09-12 2015-04-14 The Secretary Of State For Health Recombinant toxin fragments
EP1969165A4 (fr) * 2005-12-23 2010-05-19 Viventia Biotech Inc Methodes pour generer et pour cribler des bibliotheques de proteines hybrides, et leurs utilisations

Also Published As

Publication number Publication date
AU1582692A (en) 1992-10-06

Similar Documents

Publication Publication Date Title
US5602095A (en) Recombinant pseudomonas exotoxin with increased activity
FI108797B (fi) Menetelmiä humanisoitujen immunoglobuliinien tuottamiseksi sekä menetelmissä käyttökelpoinen polynukleotidimolekyyli ja solulinja
AU656352B2 (en) Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diphtheria toxin
EP0170697B1 (fr) Conjugues de toxines
WO1992015327A1 (fr) Immunotoxines bicatenaires de recombinaison
AU748097B2 (en) Directed cytolysis of target cells, agents and compositions causing cytolysis, and compounds that can be used to produce the agents
WO1989005816A1 (fr) Composes cellulaires toxiques
AU641392B2 (en) Recombinant antibody-toxin fusion protein
US5597569A (en) Bryodin 2 a ribosome-inactivating protein isolated from the plant Bryonia dioica
US6146628A (en) Biotherapeutic agents comprising recombinant PAP and PAP mutants
EP0528527B1 (fr) Conjuguées
Dunn Construction of a recombinant immunotoxin
MXPA00000643A (en) Directed cytolysis of target cells, agents and compositions causing cytolysis, and compounds that can be used to produce the agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载